1 hr ago
FSSAI Questions Companies Over Celevida GLP+ Health Claims
India’s food safety regulator has asked several companies to explain claims made about a nutrition product called Celevida GLP+.
The product was promoted as helping with protein support and keeping muscles during weight-loss treatments.
FSSAI said some of the wording might make people think the product has benefits that have not been properly established.
It also questioned statements about complete nutrition, European purity and BCAA content.
The regulator said a small disclaimer did not fix the overall impression created by the product’s name and advertising.
The companies must explain why they should not face action under food safety law.
The notices are requests for explanations, not a statement that penalties have already been imposed.
FSSAI issued notices to Dr Reddy’s, Nestle Health Science, Tirupati Wellness, Flipkart, Amazon and Netmeds.
The notices concern advertising and claims for the nutritional supplement Celevida GLP+ on e-commerce platforms.
FSSAI said claims about protein, lean-muscle preservation and muscle strength could imply benefits during GLP-1/GIP therapy.
The regulator also questioned claims about complete nutrition, European purity and 100% RDA BCAA.
The companies were directed to explain why action should not be initiated under the Food Safety and Standards Act, 2006.
- Who
- FSSAI issued notices to Dr Reddy’s, Nestle Health Science, Tirupati Wellness, Flipkart, Amazon and Netmeds.
- What
- The notices challenge allegedly non-compliant advertising and health claims for Celevida GLP+.
- Where
- The claims appeared on product packaging and e-commerce platforms in India.
- When
- The notices were announced on Thursday; one report was published on October 8, 2026.
- Why
- FSSAI said the claims could mislead consumers about the product’s health benefits and its association with GLP-1/GIP therapies.
FSSAI’s concerns
Companies’ responses
Meaning of the health claims
FSSAI’s concerns
FSSAI said the claims could imply that the product helps preserve lean mass or address muscle loss during weight loss and GLP-1/GIP therapy.
Companies’ responses
The articles do not report responses from the companies to the regulator’s concerns.
Product presentation
FSSAI’s concerns
FSSAI said the product name, therapy-related claims and other wording could create misleading impressions that a disclaimer did not correct.
Companies’ responses
The articles do not provide the companies’ position on the product’s name, advertising or packaging.
Key facts
- Regulator
- Food Safety and Standards Authority of India (FSSAI)
- Product
- Celevida GLP+
- Companies and platforms named
- Dr Reddy’s, Nestle Health Science, Tirupati Wellness, Flipkart, Amazon and Netmeds
- Claims questioned
- Protein support, lean-muscle preservation, muscle strength, immunity support and energy metabolism
- Additional representations questioned
- Complete daily nutrition, European origin as proof of purity, and 100% RDA BCAA
- Requested response
- Show cause why action should not be initiated under the Food Safety and Standards Act, 2006
- FSSAI position on disclaimer
- The disclaimer that the name was only a brand name was not sufficient to negate the overall impression, according to the regulator.
Quotes
FSSAI
India’s food safety regulator
“The concerned FBOs have been directed to show cause as to why action should not be initiated under the FSS Act, 2006.”
thehindubusinessline.com










